Company news

Rani Therapeutics Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

September 17, 2023

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

September 6, 2023

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

August 10, 2023

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

June 7, 2023

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

June 4, 2023

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 30, 2023

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 23, 2023

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

March 21, 2023

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

January 4, 2023

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

December 5, 2022

Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 9, 2022

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

October 23, 2022

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

August 10, 2022

Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock

August 9, 2022

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

August 9, 2022

Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development

August 7, 2022

Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update

March 28, 2022

Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis

March 22, 2022

Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results

February 22, 2022

Rani Therapeutics Appoints Lisa Rometty to Board of Directors

January 6, 2022

Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update

November 14, 2021

Rani Therapeutics Appoints Lyn Baranowski to Board of Directors

November 11, 2021

Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

September 12, 2021

Rani Therapeutics Announces Appointment of Eric Groen as General Counsel

September 8, 2021

Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 12, 2021

← Newer news releases

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.